Un grupo de editores de Barron´s , después de conversar con inversores, analistas, ejecutivos y otros elaboró la lista de los 30 ejecutivos más destacados.
En ella aparecen dos de la industria farmacéutica:Art Levinson de Genetech y Miles White de Abbott.
Los dos han sido noticia en PHARMACOSERÍAS, Art Levinson por la "Historia interminable" de las negociaciones con Roche, Miles White por su "escandaloso" paquete salarial...en estos tiempos de "crisis".
Estos son los comentarios de la revista y los perfiles profesionales:
"The final list is made up of chief executive officers from around the world who are doing outstanding jobs of keeping their companies out of trouble and on course. That means conservative financial management, a strong focus on the customer and relentless innovation.
The roster includes no fewer than 12 new names. Jeff Bezos of Amazon.com, for instance, has transformed his company from an online bookseller to one of the world's top retailers, with a true hot product in its Kindle wireless e-book reader. Under Jim Skinner, McDonald's started growing again as the company capitalized on healthier foods like salads, while not ignoring its core customers who crave Big Macs. In financial services, few leaders stand taller than JPMorgan Chase's Jamie Dimon, who has avoided major mishaps and become the go-to guy for regulators looking to unload crippled companies like Bear Stearns and Washington Mutual."

Art LevinsonGenentech, CEO since ’95Why: Labs of lucre.After 13 years as chief of thebiotechnology trailblazer,Art Levinson extracted a multipleof 25 times earnings from Rocheas the Swiss giant agreed thismonth to pay $95 a share for the44% of Genentech it doesn’t alreadyown.
That is double the biotech industrymultiple and a tribute tothe research productivity thatLevinson famously cultivated. Genentechgot more biotech treatmentsapproved than any rivaland has more than 100 clinical trialsunder way. Profit has grownat a 40% rate in the past fiveyears, on rising sales of cancertreatments like Rituxan, Herceptinand Avastin. Levinson’s company is one of the country’s biggestsellers of cancer drugs, in part thanks to the high pricesit commands for its innovations.Neither Roche nor Genentech has announced Levinson’srole in Genentech after it becomes a wholly owned part ofRoche, but the Swiss company said it hoped to retain himand other Genentech leaders. Roche will adopt the Genentechname for all U.S. operations. —BillAlpert